Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.

← catalyst calendar

NCT03320304 · readout in 1,200 d

Sponsored by LivaNova (industry) · LIVN — their whole pipeline →.

Phase
Status
Recruiting
Study type
Observational
Enrollment
500estimated
Sites
18
Countries
Austria, Belgium, Germany +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2017-12-14actualWhen the study began enrolling
Primary completion2029-12-01estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2031-12-01estimatedThe whole study's end, after follow-up
First posted2017-10-25actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-01-26actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Treatment Resistant Depression

Intervention

  • Device: Vagal Nerve Simulation (VNS) Therapy

Primary outcome

what the primary-completion date above is the date OF
The primary endpoint of this study is response defined as reduction in Montgomery Åsberg Depression Rating Scale (MADRS) total score of at least 50% from baseline to 12 months post implant.
measured 12 months

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · LIVN's whole pipeline · Catalyst calendar · Every registered study · What changed